Related keylists
View moreNovartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Headquarters
Switzerland
Address
Lichtstrasse 35, Basel, 4056
Website
www.novartis.com
Telephone
41 61 3241111
No of Employees
103,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NOVN (SWF)
Revenue (2022)
$51.7B
-2.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-71%
(2022 vs 2021)
Market Cap*
$235.7B
Net Profit Margin (2022)
XYZ
-70.4%
(2022 vs 2021)
* As of and is in US$
Novartis AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Medicines and Biosimilars | Cibacen (benazepril hydrochloride) |
| Pharmaceuticals: | Exforge (valsartan and amlodipine besylate) |
| Cancer | Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide) |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In September, the company announced its plans for 100% Spin-off of the Sandoz business. |
| 2023 | Plans/Strategy | In September, the company announced its plans to discontinue development of GT005 (PPY988) in Geographic Atrophy (GA) secondary to dry-Age-related Macular Degeneration (dry-AMD). |
| 2023 | Others | In September, the company and BeiGene agreed to terminate the collaboration and license agreement for tislelizumab. |
Competitor Comparison
| Key Parameters | Novartis AG | Pfizer Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | Switzerland | United States of America |
| City | Basel | New York | New Brunswick | Basel | Kenilworth |
| State/Province | - | New York | New Jersey | - | New Jersey |
| No. of Employees | 103,000 | 83,000 | 152,700 | 103,613 | 69,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joerg Reinhardt, Ph.D. | Chairman | Executive Board | 2013 | 67 |
| Vasant Narasimhan, M.D. | Chief Executive Officer | Senior Management | 2018 | 47 |
| Harry Kirsch | Chief Financial Officer | Senior Management | 2013 | 58 |
| Karen L. Hale | Chief Legal Officer | Senior Management | 2021 | 55 |
| Shreeram Aradhye | Chief Medical Officer; President - Global Drug Development | Senior Management | 2022 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward